VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
FATE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
FATEFate Therapeutics, Inc.
$2.42$282M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksFATEQuarterly Cash Flow

Fate Therapeutics, Inc. (FATE) Quarterly Cash Flow Statement

120+ quarters historyFree accessUpdated daily

Fate Therapeutics, Inc. (FATE) quarterly cash flow statement — complete operating, investing & financing history

FATE Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricQ1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23
Cash from Operations-30.82M-23.31M-24.37M-24.59M-33.81M-27.8M-29.42M-32.31M-33.35M-36.64M-38.27M-28.49M
Operating CF Margin %-2372.75%-1702.99%-1400%-1289.3%-2075.45%-1494.57%-957.03%-477.05%-1732.47%-2185.98%-1968.78%-3053.91%
Operating CF Growth %8.83%16.13%17.15%23.89%-1.38%24.12%23.13%-13.38%-15.56%51.4%30.47%46.4%
Net Income-31.21M0-32.25M-34.07M-37.62M-52.15M-47.68M-38.43M-48M-44.12M-45.17M-52.76M
Depreciation & Amortization2.15M-3.79M3.23M3.28M3.33M4.81M4.61M4.72M4.82M4.88M4.74M4.47M
Stock-Based Compensation3.93M04.86M7.15M7.38M9.12M11.77M9.63M10.98M010.1M0
Deferred Taxes000000000000
Other Non-Cash Items280K-20.58M-716K-1.02M-1.53M12.33M-1.24M-4.44M-1.76M2.79M-5.13M9.76M
Working Capital Changes-5.96M1.05M504K73K-5.37M-1.91M3.13M-3.79M614K-189K-2.82M10.04M
Change in Receivables212K-233K713K1.01M1.13M588K-2.48M-190K968K-288K1.3M10.67M
Change in Inventory000000000000
Change in Payables-5.77M865K00001.87M00-1.89M0-4.37M
Cash from Investing23.59M27.63M21.27M19.59M42.67M22.82M25.46M-53.37M17.31M45.35M24.8M33.17M
Capital Expenditures-239K-1.19M-2.2M-1.36M-1.2M-98K-495K-51K-86K-181K-565K-2.2M
CapEx % of Revenue18.4%87.07%126.54%71.42%73.42%5.27%16.1%0.75%4.47%10.8%29.06%235.69%
Acquisitions0-122K0000000000
Investments------------
Other Investing0359K3K122K00000000
Cash from Financing01.69M2.48M1.32M03.13M01.27M95.49M-180K058K
Debt Issued (Net)000000000000
Equity Issued (Net)0000000-662K75.19M-180K058K
Dividends Paid000000000000
Share Repurchases000000000000
Other Financing01.69M2.48M1.32M03.13M01.94M20.3M000
Net Change in Cash-7.24M6.01M-627K-3.67M8.86M-1.85M992K-84.41M79.45M8.54M-13.47M4.78M
Free Cash Flow-31.06M-24.51M-26.58M-25.95M-35.01M-27.9M-29.91M-32.36M-33.44M-36.82M-38.84M-30.69M
FCF Margin %-2391.15%-1790.07%-1526.54%-1360.72%-2148.86%-1499.84%-973.13%-477.81%-1736.94%-2196.78%-1997.84%-3289.6%
FCF Growth %11.27%12.16%11.16%19.8%-4.69%24.23%22.98%-5.42%-4.27%55.14%39.05%51.5%
FCF per Share-0.26-0.21-0.22-0.22-0.30-0.24-0.25-0.28-0.33-0.37-0.39-0.31
FCF Conversion (FCF/Net Income)0.99x0.72x0.76x0.72x0.90x0.53x0.62x0.84x0.69x0.83x0.85x0.54x
Interest Paid000000000000
Taxes Paid000000000000